Year |
Citation |
Score |
2020 |
Labbé M, Hoey C, Ray J, Potiron V, Supiot S, Liu SK, Fradin D. microRNAs identified in prostate cancer: Correlative studies on response to ionizing radiation. Molecular Cancer. 19: 63. PMID 32293453 DOI: 10.1186/S12943-020-01186-6 |
0.346 |
|
2020 |
Briand J, Garnier D, Nadaradjane A, Clément-Colmou K, Potiron V, Supiot S, Bougras-Cartron G, Frenel JS, Heymann D, Vallette FM, Cartron PF. Radiotherapy-induced overexpression of exosomal miRNA-378a-3p in cancer cells limits natural killer cells cytotoxicity. Epigenomics. 12: 397-408. PMID 32267172 DOI: 10.2217/Epi-2019-0193 |
0.382 |
|
2020 |
Clément-Colmou K, Potiron V, Pietri M, Guillonneau M, Jouglar E, Chiavassa S, Delpon G, Paris F, Supiot S. Influence of Radiotherapy Fractionation Schedule on the Tumor Vascular Microenvironment in Prostate and Lung Cancer Models. Cancers. 12. PMID 31906502 DOI: 10.3390/Cancers12010121 |
0.375 |
|
2019 |
Potiron V, Clément-Colmou K, Jouglar E, Pietri M, Chiavassa S, Delpon G, Paris F, Supiot S. Tumor vasculature remodeling by radiation therapy increases doxorubicin distribution and efficacy. Cancer Letters. 457: 1-9. PMID 31078733 DOI: 10.1016/J.Canlet.2019.05.005 |
0.368 |
|
2019 |
Supiot S, Rousseau C, Dore M, Chèze-Le-Rest C, Kandel-Aznar C, Potiron V, Guerif S, Paris F, Ferrer L, Campion L, Meingan P, Delpon G, Hatt M, Visvikis D. Reoxygenation during radiotherapy in intermediate-risk prostate cancer. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 133: 16-19. PMID 30935573 DOI: 10.1016/J.Radonc.2018.12.022 |
0.304 |
|
2013 |
Nasarre P, Gemmill RM, Potiron VA, Roche J, Lu X, Barón AE, Korch C, Garrett-Mayer E, Lagana A, Howe PH, Drabkin HA. Neuropilin-2 Is upregulated in lung cancer cells during TGF-β1-induced epithelial-mesenchymal transition. Cancer Research. 73: 7111-21. PMID 24121493 DOI: 10.1158/0008-5472.Can-13-1755 |
0.78 |
|
2011 |
Gemmill RM, Roche J, Potiron VA, Nasarre P, Mitas M, Coldren CD, Helfrich BA, Garrett-Mayer E, Bunn PA, Drabkin HA. ZEB1-responsive genes in non-small cell lung cancer. Cancer Letters. 300: 66-78. PMID 20980099 DOI: 10.1016/J.Canlet.2010.09.007 |
0.784 |
|
2011 |
Potiron V, Drabkin H, Roche J. SEMA3F (sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3F) Atlas of Genetics and Cytogenetics in Oncology and Haematology. DOI: 10.4267/2042/44387 |
0.559 |
|
2010 |
Nasarre P, Potiron V, Drabkin H, Roche J. Guidance molecules in lung cancer. Cell Adhesion & Migration. 4: 130-45. PMID 20139699 DOI: 10.4161/Cam.4.1.10882 |
0.783 |
|
2010 |
Roche J, Nasarre P, Potiron V, Nair-Menon J, Gemmill R, Drabkin H. Abstract 4969: Neuropilin-2 is downregulated by Snail during EMT in lung cancer Cancer Research. 70: 4969-4969. DOI: 10.1158/1538-7445.Am10-4969 |
0.803 |
|
2009 |
Clarhaut J, Gemmill RM, Potiron VA, Ait-Si-Ali S, Imbert J, Drabkin HA, Roche J. ZEB-1, a repressor of the semaphorin 3F tumor suppressor gene in lung cancer cells. Neoplasia (New York, N.Y.). 11: 157-66. PMID 19177200 DOI: 10.1593/Neo.81074 |
0.801 |
|
2009 |
Potiron VA, Roche J, Drabkin HA. Semaphorins and their receptors in lung cancer. Cancer Letters. 273: 1-14. PMID 18625544 DOI: 10.1016/J.Canlet.2008.05.032 |
0.702 |
|
2008 |
Karayan-Tapon L, Wager M, Guilhot J, Levillain P, Marquant C, Clarhaut J, Potiron V, Roche J. Semaphorin, neuropilin and VEGF expression in glial tumours: SEMA3G, a prognostic marker? British Journal of Cancer. 99: 1153-60. PMID 18781179 DOI: 10.1038/Sj.Bjc.6604641 |
0.742 |
|
2007 |
Potiron VA, Sharma G, Nasarre P, Clarhaut JA, Augustin HG, Gemmill RM, Roche J, Drabkin HA. Semaphorin SEMA3F affects multiple signaling pathways in lung cancer cells. Cancer Research. 67: 8708-15. PMID 17875711 DOI: 10.1158/0008-5472.Can-06-3612 |
0.756 |
|
2007 |
Loudni L, Roche J, Potiron V, Clarhaut J, Bachmann C, Gesson JP, Tranoy-Opalinski I. Design, synthesis and biological evaluation of 1,4-benzodiazepine-2,5-dione-based HDAC inhibitors. Bioorganic & Medicinal Chemistry Letters. 17: 4819-23. PMID 17624773 DOI: 10.1016/J.Bmcl.2007.06.067 |
0.737 |
|
2007 |
Potiron V, Nasarre P, Roche J, Healy C, Boumsell L. Semaphorin signaling in the immune system. Advances in Experimental Medicine and Biology. 600: 132-44. PMID 17607952 DOI: 10.1007/978-0-387-70956-7_11 |
0.739 |
|
2005 |
Kusy S, Potiron V, Zeng C, Franklin W, Brambilla E, Minna J, Drabkin HA, Roche J. Promoter characterization of Semaphorin SEMA3F, a tumor suppressor gene. Biochimica Et Biophysica Acta. 1730: 66-76. PMID 16005989 DOI: 10.1016/J.Bbaexp.2005.05.008 |
0.652 |
|
2005 |
Kusy S, Nasarre P, Chan D, Potiron V, Meyronet D, Gemmill RM, Constantin B, Drabkin HA, Roche J. Selective suppression of in vivo tumorigenicity by semaphorin SEMA3F in lung cancer cells. Neoplasia (New York, N.Y.). 7: 457-65. PMID 15967098 DOI: 10.1593/Neo.04721 |
0.79 |
|
2005 |
Potiron V, Roche J. Class 3 semaphorin signaling: the end of a dogma. Science's Stke : Signal Transduction Knowledge Environment. 2005: pe24. PMID 15914725 DOI: 10.1126/Stke.2852005Pe24 |
0.65 |
|
Show low-probability matches. |